Literature DB >> 26104380

The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation.

Hai-Hua Sun1, Dong-Fang Zhou1, Jun-Ying Zhou1.   

Abstract

Chronic hepatitis B virus (HBV) infection is the result of an inadequate immune response towards the virus. Dendritic cells (DCs), as the most efficient professional antigen-presenting cells (APCs), possess the strongest antigen presenting the effect in the body and can stimulate the initial T cell activation and proliferation. DCs of patients with chronic HBV infection are impaired, resulting in more tolerogenic rather than immunogenic responses, which may contribute to viral persistence. Recently, numerous methods have been developed to induce DCs maturation. To date, recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) combined with interleukin-4 (rhIL-4) has been a classic culture combination to DCs. The recently classified type III interferon group interferon-λ (IFN-λ) displays antiviral, antitumor, and immunoregulatory activity. In our laboratory, we demonstrate that IFN-λ1 combined with rhGM-CSF and rhIL-4 can significantly increase the expression of DC surface molecules and the secretion of interleukin-12 (IL-12) and interferon-γ (IFN-γ) in patients with chronic hepatitis B infection. In this review, we emphasize on the role of DCs in the immunopathogenesis of chronic HBV infection. Importantly, we systematic review that the latest update in the current status of knowledge on the methods of inducing DCs maturation in anti-HBV immunity. What's more, we conclude that IFN-λ1 combined with GM-CSF and IL-4 can induce DCs maturation, which could become a possibility to be applied to the autologus dendritic cell vaccine to treat chronic hepatitis B.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  DCs maturation; autologus dendritic cell vaccine; dendritic cells; hepatitis B virus; interferon-λ

Mesh:

Substances:

Year:  2015        PMID: 26104380     DOI: 10.1002/jmv.24306

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment.

Authors:  Weihua Cao; Si Xie; Lu Zhang; Xiaoyue Bi; Yanjie Lin; Liu Yang; Yao Lu; Ruyu Liu; Min Chang; Shuling Wu; Ge Shen; Jianping Dong; Yao Xie; Minghui Li
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 2.  The Multiple Functions of B Cells in Chronic HBV Infection.

Authors:  Ying Cai; Wenwei Yin
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 3.  The Role of Immune Cells in Chronic HBV Infection.

Authors:  Hai-Jun Li; Nai-Cui Zhai; Hong-Xiao Song; Yang Yang; An Cui; Tian-Yang Li; Zheng-Kun Tu
Journal:  J Clin Transl Hepatol       Date:  2015-12-15

Review 4.  The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses.

Authors:  Jorge A Soto; Nicolas M S Gálvez; Catalina A Andrade; Gaspar A Pacheco; Karen Bohmwald; Roslye V Berrios; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

5.  Clearance of HBeAg and HBsAg of HBV in mice model by a recombinant HBV vaccine combined with GM-CSF and IFN-α as an effective therapeutic vaccine adjuvant.

Authors:  Weidong Zhao; Gan Zhao; Shuren Zhang; Xianzheng Wang; Xueping Yu; Bin Wang
Journal:  Oncotarget       Date:  2018-07-13

6.  Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo.

Authors:  Olesya Chornoguz; Catherine N Leettola; Karen Leander; Kerry Brosnan; Eva Emmell; Mark L Chiu; Sandra Santulli-Marotto
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2019-12

Review 7.  Role of alcohol in pathogenesis of hepatitis B virus infection.

Authors:  Murali Ganesan; Allison Eikenberry; Larisa Y Poluektova; Kusum K Kharbanda; Natalia A Osna
Journal:  World J Gastroenterol       Date:  2020-03-07       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.